Thursday, April 21, 2016 8:01:36 PM
Program Number: 1280 Poster Board Number: D0228
Presentation Time: 3:15 PM–5:00 PM
sd-rxRNA®: Self-Delivering RNAi Compounds Show Potential
for Corneal Indications Following Topical Application
Michael Byrne, Melissa Maxwell, Richard Looby, Katherine Holton,
James Cardia, Lyn Libertine, Pamela A. Pavco, Karen Bulock.
OPHTHALMOLOGY, RXi Pharmaceuticals, Marlborough, MA.
Purpose: sd-rxRNA® are stable oligonucleotides that have features
of RNAi and antisense and result in spontaneous cellular uptake.
When dosed by intravitreal injection sd-rxRNAs are taken up by all
cell layers of the retina within 24 hours and result in dose-dependent,
target-specific mRNA reduction for as long 3 weeks. RXI-109 is an
sd-rxRNA, targeting connective tissue growth factor (CTGF), being
evaluated in a Phase 1/2 clinical trial for subretinal fibrosis associated
with wet AMD. When RXI-109 is dosed by intravitreal injection to
non-human primate, dose-dependent protein reduction is noted in
the retina and the cornea for at least 1 week. Current ocular clinical
focus is to reduce the progression of scarring in the back of the eye.
Scarring is also a major concern for many front of the eye indications,
specifically those involving the cornea.
Here we present new data highlighting topical delivery of sd-rxRNA
to the cornea, administered as eye drops or formulated in a thermoreversible
gel, in the presence of an epithelial injury.
Methods: An 8 mm epithelial wound was created on the cornea of
rabbits. sd-rxRNA was dosed topically 4 times a day for 1 day as
eye drops or in a thermo-reversible gel. A second group of animals
with an intact epithelial layer of the cornea were exposed to the same
dosing regimen. At 24 and 48 hours post application, whole eyes
were processed for histological evaluation of cornea cellular uptake
of sd-rxRNA.
Results: Macroscopically, compound was visible in the cornea in the
injured cornea group at 24 hours post dose. The intensity was less at
48 hours. Microscopically, fluorescent sd-rxRNA was visible through
all layers of the cornea in the presence of an epithelial injury at 24
hours when formulated in the thermo-reversible gel, and through
the majority of layers when administered as drops. Cellular delivery
continued to be detectable at 48 hours. No cellular uptake was visible
in the cornea when the epithelial layer was intact.
Conclusions: sd-rxRNA compounds are stable compounds requiring
no additional delivery vehicle to be taken up by cells. RXI-109, a
CTGF-targeting sd-rxRNA being developed to reduce scarring, is
in a Phase 1/2 clinical trial for subretinal fibrosis associated with
late-stage wet AMD. Here we provide evidence of the potential of the
sd-rxRNA platform for development of topical therapeutics for front
of the eye indications.
Commercial Relationships: Michael Byrne, RXi Pharmaceuticals;
Melissa Maxwell, RXi Pharmaceuticals; Richard Looby, RXi
Pharmaceuticals; Katherine Holton, RXi Pharmaceuticals;
James Cardia, RXi Pharmaceuticals; Lyn Libertine, RXi
Pharmaceuticals; Pamela A. Pavco, RXi Pharmaceuticals;
Karen Bulock, RXi Pharmaceuticals
Recent PHIO News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2024 09:00:13 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/20/2024 09:03:23 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 05/20/2024 08:59:26 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/17/2024 08:45:23 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/17/2024 01:04:34 PM
- Phio Pharmaceuticals Secures New Investor • GlobeNewswire Inc. • 05/17/2024 01:00:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 01:00:13 PM
- Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID) • GlobeNewswire Inc. • 05/16/2024 12:00:00 PM
- Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study • GlobeNewswire Inc. • 05/15/2024 05:00:00 PM
- Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 09:25:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 09:23:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 09:20:56 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/08/2024 09:04:03 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/08/2024 09:02:05 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/08/2024 09:00:34 PM
- Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO) • GlobeNewswire Inc. • 04/30/2024 11:30:00 AM
- Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells • GlobeNewswire Inc. • 04/22/2024 05:10:09 PM
- Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID) • GlobeNewswire Inc. • 04/16/2024 11:30:00 AM
- Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT) • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- National Spotlight Features Phio’s Innovative RNAi Technology Platform • GlobeNewswire Inc. • 04/03/2024 11:30:00 AM
- Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update • GlobeNewswire Inc. • 04/02/2024 11:30:00 AM
- Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies • GlobeNewswire Inc. • 03/21/2024 11:30:00 AM
- Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research • GlobeNewswire Inc. • 03/13/2024 06:00:25 PM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM